 BOSTON and LOUISVILLE, Ky., March 22, 2022 GLOBE NEWSWIRE -- Talaris Therapeutics, Inc. Nasdaq: TALS, a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today announced that members of its senior management team will participate at the following investor conferences: 